These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 16506388

  • 1. The role of a protease inhibitor against hepatectomy.
    Gotohda N, Iwagaki H, Ozaki M, Konishi M, Nakagohri T, Takahashi S, Yagi T, Kinoshita T, Tanaka N.
    Hepatogastroenterology; 2006; 53(67):115-9. PubMed ID: 16506388
    [Abstract] [Full Text] [Related]

  • 2. Significant correlation between surgical stress of hepatectomy and changes in the serum levels of HGF, IL-6 and soluble Fas in patients with viral hepatitis.
    Gotohda N, Iwagaki H, Ozaki M, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Saito S, Yagi T, Tanaka N.
    Hepatogastroenterology; 2008; 55(85):1400-3. PubMed ID: 18795698
    [Abstract] [Full Text] [Related]

  • 3. Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma.
    Hu RH, Lee PH, Yu SC, Sheu JC, Lai MY.
    Hepatogastroenterology; 1999; 46(27):1842-7. PubMed ID: 10430357
    [Abstract] [Full Text] [Related]

  • 4. Deficient response of IL-6 impaired liver regeneration after hepatectomy in patients with viral hepatitis.
    Gotohda N, Iwagaki H, Ozaki M, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Saito S, Yagi T, Tanaka N.
    Hepatogastroenterology; 2008; 55(85):1439-44. PubMed ID: 18795707
    [Abstract] [Full Text] [Related]

  • 5. Serum interleukin-6 and hepatocyte growth factor levels in patients after hepatectomy.
    Chijiiwa K, Saiki S, Tanaka M.
    Hepatogastroenterology; 2002; 49(44):467-71. PubMed ID: 11995475
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, Lee PC, Chi CW, Lui WY, Lee SD.
    Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
    [Abstract] [Full Text] [Related]

  • 7. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
    Coskun U, Bukan N, Sancak B, Günel N, Ozenirler S, Unal A, Yucel A.
    Neoplasma; 2004 Mar; 51(3):209-13. PubMed ID: 15254675
    [Abstract] [Full Text] [Related]

  • 8. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma.
    Tamesa T, Iizuka N, Mori N, Okada T, Takemoto N, Tangoku A, Oka M.
    Hepatogastroenterology; 2009 Mar; 56(93):1122-6. PubMed ID: 19760954
    [Abstract] [Full Text] [Related]

  • 9. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
    Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW.
    Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
    [Abstract] [Full Text] [Related]

  • 10. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
    Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W.
    Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
    [Abstract] [Full Text] [Related]

  • 11. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS, Zheng SS, Wu LJ, Ding W, Ma ZM, Wang ZM, Teng LS, Zhao WH.
    Zhonghua Wai Ke Za Zhi; 2006 May 01; 44(9):603-8. PubMed ID: 16784653
    [Abstract] [Full Text] [Related]

  • 12. Serum transforming growth factor-alpha level can be a parameter for evaluating liver regeneration after partial hepatectomy in patients with liver cancer.
    Tomiya T, Hayashi S, Yanase M, Umeda N, Tani M, Yamada S, Masaki N, Ogata I, Fujiwara K.
    Semin Oncol; 1997 Apr 01; 24(2 Suppl 6):S6-14-S6-17. PubMed ID: 9151911
    [Abstract] [Full Text] [Related]

  • 13. Portal serum human hepatocyte growth factor levels after partial hepatectomy.
    Higaki I, Yamazaki O, Matsuyama M, Horii K, Kawai S, Hirohashi K, Kinoshita H.
    Hepatogastroenterology; 1999 Apr 01; 46(26):1078-82. PubMed ID: 10370670
    [Abstract] [Full Text] [Related]

  • 14. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
    Kitaoka S, Shiota G, Kawasaki H.
    Hepatogastroenterology; 2003 Apr 01; 50(53):1569-74. PubMed ID: 14571788
    [Abstract] [Full Text] [Related]

  • 15. Clarification of risk factors for hepatectomy in patients with hepatocellular carcinoma.
    Ishikawa M, Yogita S, Miyake H, Fukuda Y, Harada M, Wada D, Tashiro S.
    Hepatogastroenterology; 2002 Apr 01; 49(48):1625-31. PubMed ID: 12397750
    [Abstract] [Full Text] [Related]

  • 16. The analysis of the usefulness of laparoscopic microwave coagulation therapy for hepatocellular carcinoma in patients with poor hepatic reserve by serial measurements of IL-6, cytokine antagonists, and C-reactive protein.
    Sadamori H, Yagi T, Kanaoka Y, Morimoto Y, Inagaki M, Ishikawa T, Matsukawa H, Matsuda H, Iwagaki H, Tanaka N.
    Surg Endosc; 2003 Mar 01; 17(3):510-4. PubMed ID: 12399851
    [Abstract] [Full Text] [Related]

  • 17. Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor.
    de Jong KP, Hoedemakers RM, Fidler V, Bijzet J, Limburg PC, Peeters PM, de Vries EG, Slooff MJ.
    Scand J Gastroenterol; 2004 Nov 01; 39(11):1141-8. PubMed ID: 15545174
    [Abstract] [Full Text] [Related]

  • 18. The significance of serum hepatocyte growth factor levels in planning follow-up of postoperative jaundice-free patients with biliary atresia.
    Uchida K, Inoue M, Otake K, Yoshiyama S, Toiyama Y, Hiro J, Araki T, Miki C, Kusunoki M.
    J Pediatr Surg; 2006 Oct 01; 41(10):1657-62. PubMed ID: 17011264
    [Abstract] [Full Text] [Related]

  • 19. Human hepatocyte growth factor in bile: an indicator of posthepatectomy liver function in patients with biliary tract carcinoma.
    Takeuchi E, Nimura Y, Nagino M, Kurumiya Y, Maeda A, Kamiya J, Kondo S, Kanai M, Miyachi M, Uesaka K, Yoshida S.
    Hepatology; 1997 Nov 01; 26(5):1092-9. PubMed ID: 9362347
    [Abstract] [Full Text] [Related]

  • 20. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.
    Osada S, Kanematsu M, Imai H, Goshima S.
    Hepatogastroenterology; 2008 Nov 01; 55(82-83):544-9. PubMed ID: 18613405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.